TMCnet News

SolaranRx to Present Novel Metastatic Melanoma Treatment at Sachs Cancer Bio Partnering & Investment Forum in New York
[February 18, 2015]

SolaranRx to Present Novel Metastatic Melanoma Treatment at Sachs Cancer Bio Partnering & Investment Forum in New York


SolaranRx, Inc., which is developing a peptide-based technology for treating metastatic melanoma, is among the featured presenters at the Third Annual Sachs Cancer Bio Partnering & Investment Forum on February 23 at the New York Academy of Sciences in New York City. SolaranRx's lead product, SRX-1177, was recently selected among the 2014 Top 10 Most Interesting Oncology Projects to Watch by Informa (News - Alert) and Kantar Health for its strong science and potential to address unmet medical needs in treating metastatic melanoma.

The Sachs Cancer Bio Partnering & Investment Forum is designed to bring together hought leaders from cancer research institutes, patient advocacy groups, pharma, and biotech to facilitate partnering and investment in drug development. Around 200 delegates are anticipated to attend. SolaranRx is one of just 30 listed and private biotechnology companies invited to present their technologies.



SolaranRx's lead product, SRX-1177, is a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-1177 to deliver targeted radiation to cancer cells, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.

"We are pleased to present our distinctive technology for treating metastatic melanoma at the Sachs forum, which is recognized as a powerful venue for promoting collaboration and partnerships among key stakeholders," said SolaranRx CEO Les Stewart. "We expect to generate significant interest in our treatment technology. Current treatments are ineffective for a significant number of patients, have serious, sometimes fatal side effects, and are costly to the healthcare system. Our peptide-based technology has the potential to offer physicians a new, more cost-efficient therapeutic option with fewer side effects for these patients."


About SolaranRx, Inc.

SolaranRx, Inc. is driven to develop a new class of therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics-often referred to as theranostics-constitutes a new level of personalized medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patients' quality of life, giving new options to clinicians and hope to patients. Visit www.SolaranRx.com.


[ Back To TMCnet.com's Homepage ]